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Randomised controlled trials form an important part of the evidence 
supporting surgical innovation. The Leopard-2 trial of laparoscopic versus 
open pancreatoduodenectomy for pancreatic or periampullary cancer was 
stopped early due to safety concerns when it became clear that after 
randomisation of 99 patients proceeding to surgery there was a 5 fold 
increase in 90 day mortality in the laparoscopic surgery arm1.  
We are interested in the consequences of the early termination of clinical trials 
for subsequent systematic reviews and meta-analyses. Clearly the early 
cessation of a trial on safety grounds is justifiable, however, it creates an 
interesting problem in interpretation. It could be presumed that had the 
Leopard 2 trial been allowed to continue it might have shown an adverse 
effect of laparoscopic pancreatoduodenectomy that would have had statistical 
power. Clearly this would have been at a human cost and so is unacceptable. 
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Researchers studying the question of equivalence or superiority of 
laparoscopic or open pancreatoduodenectomy are likely to pool data from the 
Leopard 2 trial into meta-analyses and there is no specific guidance about 
how to handle such data. The PRISMA statement2 describes the need to 
describe sources of potential bias in the methodology or results presentation 
of clinical trials but does not specifically comment on the issue of early 
cessation of clinical trials due to adverse or unfavourable outcomes.  
 
Trials which are stopped early following analysis of interim data are likely to 
show more extreme intervention effects than those which enroll their intended 
sample size particularly in trials with rare events3,4. Further trials investigating 
the same hypothesis are unlikely to replicate the extreme point estimate 
obtained in the truncated trial, a feature known as “regression to the truth”. 
Whilst much of the existing debate over the influence of truncated trials has 
focused on inappropriate adoption of novel treatments following truncated 
trials demonstrating benefit5, trials stopped early for harm are subject to the 
same biases. Researchers, clinicians and policy-makers will undoubtedly 
make decisions, which incorporate evidence from truncated trials, such as the 
Leopard 2 trial, which raise ethical and practical concerns about how such 
trials are interpreted. Potential implications of decisions made on the basis of 
results from the Leopard 2 trial include misleading summary effects from 
meta-analyses, a potential “freezing” effect on the conduct of similar trials and 
interpretation of the large effect size as irrefutable evidence of harm despite a 
lack of statistical significance or data available from other trials.   
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